Why I'm Increasing My Position in Rocket Doctor AI While the Market Keeps Ignoring It

Disclosure up front: I am long Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | FSE: 939)

On August 11, Rocket Doctor announced it had gone in-network with another major national insurer in New York — adding more than 100,000 eligible covered lives across Medicare Advantage PPO and commercial plans in the New York City metro region and select upstate counties.

If you only read the headline number, you will underreact. If you read what’s underneath it, you’ll see why I’m adding.

Let me be honest about both.

1. What was actually announced

Straight from the release, so we’re working from the same facts:

• More than 100,000 additional eligible covered lives across individual Medicare Advantage PPO and commercial plans.
• Geography: NYC metro region plus select upstate counties.
• The payer participates in a national reciprocal network program, meaning eligible out-of-state plan members can access Rocket Doctor’s in-network physicians while travelling in New York.
• The estimate excludes members covered under administrative services-only (ASO) or self-insured plans.
• The agreement was signed on July 15, 2026, and announced on August 11. Initial one-year term, automatic one-year renewals unless terminated.
• Running total: ~10 million covered lives in New York, ~24 million across the U.S.

That last number matters. The Q1 2026 MD&A put the total at approximately 21 million covered lives across California, New York and Maryland. We’re now at roughly 24 million. That’s meaningful movement in a single quarter, and it happened without a single press release that moved the stock in any durable way.

2. 100,000 is the wrong number to anchor on

Let’s kill the obvious criticism first, because it’s a fair one.

100,000 lives on a 24 million base is a 0.4% increase. On its own, that is not a stock-moving event, and anyone telling you it is doesn’t understand the math. I’m not going to pretend otherwise.

What I actually care about is the composition.

This is Medicare Advantage PPO and commercial. Those are not Medicaid managed care lives. In U.S. virtual care, reimbursement per encounter is not uniform — Medicare Advantage and commercial lines generally reimburse at higher rates than Medicaid, and Medicare Advantage members are, by definition, an older and higher-utilization population. Rocket Doctor’s early U.S. footprint was heavily weighted toward Medicaid and Medicare/Dual-Eligible. Adding commercial and MA PPO shifts the quality of the covered-life base, not just the count.

The reciprocal network detail is the other piece most people will skim past. A national reciprocal program means eligible members of that plan from outsideNew York can use Rocket Doctor’s in-network physicians while they’re in the state. It’s a small structural widening of the funnel that doesn’t show up in the headline count at all, and neither do the ASO and self-insured members, the company explicitly excluded from its estimate.

So: small number, better-quality number, and a conservatively stated number. That combination is what I’m paying for.

3. The gap is the entire thesis

Here is the setup in one comparison, and it is the reason I own this at all.

Contracted, in-network access: ~24 million covered lives. Q1 2026 reported revenue: C$737,103.

That’s the whole trade. Rocket Doctor has spent three-plus years building payer contracts, credentialing infrastructure and revenue operations specific to Medicaid and Medicare, and the market is pricing the company off a P&L that reflects almost none of it.

Management’s own language in the Q1 MD&A is that less than 3% of the projected revenues associated with the newly finalized payer agreements are reflected in current financial statements. That’s a management estimate, not an audited figure, and you should treat it as such. But the direction is not in dispute: the contracts exist, the revenue does not yet.

I’ve written before that this is a before picture still being priced by the market. Nothing in this release changes that. It extends it.

4. The bottleneck is credentialing supply, not patient demand

This is the part I’d want any skeptic to sit with.

Rocket Doctor does not have a demand problem. Per the Q1 MD&A, monthly completed U.S. patient visits rose 283% during Q1 2026, and April 2026 came in around 1,200 completed visits, a further 69% month-over-month increase. (The July investor deck cites 1,144 for April; I’d use the deck’s more precise figure and treat ~1,200 as rounding in the MD&A.)

What it has is a supply problem. The number of active providers and specialists on the platform roughly doubled by the end of May 2026.

Very few physicians. Twenty-four million covered lives.

That ratio is the thesis and the risk in a single line. Every new payer agreement expands the addressable pool. None of them converts to revenue faster than the company can credential physicians into those networks. Credentialing is measured in months; it is payer-by-payer and state-by-state, and it does not accelerate because a press release went out.

So when I track this name, I am no longer tracking covered lives. I’m tracking active credentialed physician count and pipeline. That is the forward-looking number. Everything else is downstream of it.

5. Why the reported revenue understates what’s happening

One structural point that I think the market genuinely misreads.

For its U.S. operations, Rocket Doctor recognizes revenue on a cash basis, not when the visit occurs, but when payment is actually received. The MD&A is explicit that collectability cannot be established with sufficient certainty at the time of service to satisfy IFRS 15, given varying collection timelines across payers.

The practical consequence: a visit completed in July may not appear as revenue until Q4. There is a structural lag of roughly 45–90 days between visit volume and reported revenue.

I’d argue that is conservative accounting, not a weakness. It means reported revenue is a lagging, cash-confirmed indicator of an operating business that has already grown past what the income statement shows. It also means Q2 and Q3 prints are the real test, that’s where the Q1 visit surge should begin landing.

If it doesn’t land there, my thesis has a problem. I’ll say so when the numbers come out.

6. What else happened this week

On August 5, Rocket Doctor entered a digital advisory agreement with B2i Digital, joining its Featured Company Program and its self-described network of more than 1.7 million retail and institutional market participants.

Two things worth stating plainly. First, the 1.7 million figure is self-reported by B2i and its methodology is not publicly defined; treat it accordingly. Second, IR spend is immaterial relative to this company’s burn, so “is it accretive” is the wrong question. The right question is sequencing: the company is spending on investor awareness roughly six months ahead of a January 2027 warrant expiry at $0.85. If the stock is above $0.85 into that window, roughly C$6.3 million in non-dilutive proceeds unlock. If it isn’t, those warrants expire worthless, and the company raises again on worse terms.

That’s the actual logic. Whether it works is a separate question.

7. What would prove me wrong

I don’t publish a thesis without naming its failure conditions:

1. Credentialed physician count stalls. If active providers sit still through Q3, the number of covered lives is decorative.
2. Q3 and Q4 revenue doesn’t inflect. Cash-basis lag explains a quarter. It does not explain two.
3. Additional debenture tranches close on terms similar to or worse than those.
4. Covered lives keep growing while revenue per covered life stays flat. That would mean access is being signed but not converted, and the press-release cadence would be running well ahead of the business.
5. Payer non-renewal. This agreement has an initial term of 1 year. So do others. Access can be withdrawn.

Why am I adding anyway?

Because I think the market is pricing a company with C$737K of quarterly revenue, and I think it is buying an infrastructure position, payer contracts, credentialing workflows, revenue operations, that took three and a half years to build and that a competitor cannot replicate with capital alone.

Because the constraint is credentialing throughput, which is a solvable operational problem, not a demand problem. Demand problems kill companies. Throughput problems get fixed.

Because the covered-life base is growing and improving in mix, Medicare Advantage PPO and commercial are better lives than the Medicaid base the company started with.

And because the financing terms that make this uncomfortable are exactly why the price is where it is. If the balance sheet were clean and the credentialing pipeline were full, it would not be trading at the current valuation. I’d be reading about it in a research note.

The risk is real. The dilution is real. I’m sizing accordingly; over 6% is a conviction position, not a bet-the-portfolio position, and it stays that way until the Q2 and Q3 numbers tell me something new.

The next thing I’m watching is not a press release. It’s the credentialed physician count.

Sources: Company press releases via GlobeNewswire (August 5, 6 and 11, 2026); Rocket Doctor AI Inc. Q1 2026 interim MD&A and condensed interim consolidated financial statements (three months ended March 31, 2026, filed on SEDAR+); Rocket Doctor AI July 2026 investor presentation; Maxim Group initiation of coverage (January 2026); Fundamental Research Corp. update (May 2026).

Note on analyst coverage: Maxim Group rates AIDR Buy with a C$3.00 target and makes the security a market. Fundamental Research Corp. rates it Buy with a C$1.86 fair value estimate and is a paid-coverage provider. Both conflicts are disclosed in their own reports. Weight them accordingly.

Note on per-visit economics: Maxim’s initiation models a flat fee of US$18 per U.S. appointment. The company’s July 2026 investor deck cites US$25 per U.S. appointment. I have not been able to reconcile these from filed disclosures, and I’m flagging the discrepancy rather than picking a side.

Disclosure: I am long Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | FSE: 939). The position now accounts for over 6% of my equity portfolio, and I have recently added to it. I receive no compensation for this or any other piece I write about AIDR. I may buy or sell at any time without notice. This is a micro-cap company with negative cash flow, going-concern language in its filings, and an active dilutive financing underway. It is not suitable for every investor. NFA. DYOR.